Aegis Capital Downgrades Acasti Pharma (ACST) to Hold, After Pharma Study Not Meeting Endpoints
Tweet Send to a Friend
Aegis Capital analyst Nathan Weinstein downgraded Acasti Pharma (NASDAQ: ACST) from Buy to Hold with a price target of $0.25 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
